A shift from demerol (meperidine) to dilaudid (hydromorphone) improves pain control and decreases admissions for patients in sickle cell crisis

J Emerg Nurs. 2004 Oct;30(5):439-46. doi: 10.1016/j.jen.2004.06.016.
No abstract available

MeSH terms

  • Anemia, Sickle Cell / drug therapy*
  • Clinical Protocols*
  • Emergency Service, Hospital / organization & administration*
  • Humans
  • Hydromorphone / administration & dosage*
  • Meperidine / administration & dosage*
  • Pain / prevention & control*
  • Pain Measurement
  • Patient Admission / statistics & numerical data
  • Program Evaluation

Substances

  • Meperidine
  • Hydromorphone